Zydus receives final approval from USFDA for Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari® (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg (USRLD: Emflaza® Tablets, 6 mg, 18mg, 30 mg, and 36 mg).

Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Jaythari® (Deflazacort) will be produced at Doppel Farmaceutici S.r.l., Italy facility.

The group now has 424 approvals and has so far filed 492* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 868.25 as compared to the previous close of Rs. 844.60. The total number of shares traded during the day was 66227 in over 3397 trades.

The stock hit an intraday high of Rs. 876.95 and intraday low of 855.15. The net turnover during the day was Rs. 57331691.00.

(*As on 31st March, 2025.)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals USFDA Approval Jaythari Deflazacort Tablets